--- canonical_url: https://www.stockexpertai.com/earnings/hsic last_updated: 2026-05-09T16:49:38.016Z --- # Henry Schein, Inc. (HSIC) Q1 FY2027 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T16:49:37.567Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $70.82 (▲ 0.45%) | fmp:quote | | Market Cap | $8.1B | fmp:profile | | 52w range | $61.95 – $89.29 | fmp:quote | | Earnings | Tue 4 Aug | fmp:earnings-history | | EPS estimate | $1.19 (+8% YoY) | fmp:earnings-estimate | | Revenue estimate | $3.4B | fmp:earnings-estimate | | Beat streak | 3/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $86 (+21.4% upside) | fmp:price-target-consensus | | MoonshotScore | 30/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Henry Schein, Inc. — Q1 FY2027 Expectations Q1 consensus: revenue $3.4B^{[FMP est]}, EPS $1.19^{[FMP est]}. 3 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 30 = MoonshotScore 30^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Ecommerce Platform Rollout Henry Schein has successfully rolled out its global e-commerce platform, henryschein.com to our Canadian and U.S. laboratory customers and expects to complete the U.S. rollout by the end of August. > "We have also successfully rolled out our global e-commerce platform, henryschein.com to our Canadian and U.S. laboratory customers. We are well advanced in implementation across the U.S. with over 80% of our U.S. dental e-commerce sales now transacted over henryschein.com. We expect to complete the U.S. rollout by the end of August" > — Frederick Lowery, Investor Focus · Q1 FY2026 ### 2. Operating Income Improvement Henry Schein is committing to the company's goal of achieving greater than $200 million of annual operating income improvement within the next few years with $125 million run rate by the end of 2026. > "Therefore, I am committing to the company's goal of achieving greater than $200 million of annual operating income improvement within the next few years with $125 million run rate by the end of 2026." > — Frederick Lowery, Investor Focus · Q1 FY2026 ### 3. Ai Clinical Workflow Henry Schein's next-generation AI clinical workflow is a clear signal that our customers are ready to embrace these tools and that Henry Schein is well positioned to lead that transition. > "The broad level of interest in our AI solutions was a clear signal that our customers are ready to embrace these tools and that Henry Schein is well positioned to lead that transition." > — Frederick Lowery, Investor Focus · Q1 FY2026 ### 4. Market Share Gains Henry Schein is gaining market share in the U.S. dental market, and dental markets overall remain stable and healthy. > "The dental markets remain stable and healthy, and we are gaining market share." > — Frederick Lowery, Investor Focus · Q1 FY2026 ### 5. Dso Investment Equipment Dental practices and, in particular, DSOs are continuing to invest in equipment, and we are seeing DSOs gaining market share in the overall dental market. > "Dental practices and, in particular, DSOs are continuing to invest in equipment, and we are seeing DSOs gaining market share in the overall dental market." > — Frederick Lowery, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 2.0 | weak | Q1 vs Q2: moderate growth (+4.0%) | | Gross Margin | 3.0 | weak | Q1: average margin (31.8%) | | Operating Leverage | 1.0 | weak | op margin average (5.4%) | | Cash Runway | 3.0 | weak | FCF negative ($-0.1B, external financing needed) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 4.0 | medium | RSI 35.7 weak momentum, 50d below | | News Sentiment | 5.0 | medium | majority buy (50%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +21.4% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 36 | | Klarman | neutral | value · target upside +21.4% | | Buffett | bull | quality · ROE score 4/5 | | Munger | neutral | valuation · target upside +21.4% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 35.7 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $76 — hisse %6.4 altında — kısa vadeli direnç - **200d MA:** $73 — hisse %2.5 altında — uzun vadeli baskı - **Volume (10d):** -23% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.10 | $1.18 | MISS | +2.3% | | Q3 FY25 | $1.38 | $1.27 | BEAT | +0.6% | | Q4 FY25 | $1.34 | $1.30 | BEAT | -1.7% | | Q1 FY26 | $1.32 | $1.20 | +10.0% EPS | -2.6% | Q1 (May 5, 2026): EPS $1.32 vs $1.20 est^[FMP], +10.0% beat. D+1 movement: -2.6%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q1 EPS > $1.19 + CapEx discipline** Threshold: EPS > $1.19^{[FMP est]}. Target: Break above median target $86^{[FMP target]}; high target $97^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.19 + CapEx < $39.0M** Threshold: EPS ≈ $1.19^{[FMP est]}, Q1 CapEx < $39.0M^[FMP]. Target: Consolidation in the band between current $71^[FMP] and median $86^[FMP]. ### Scenario C · Miss **EPS < $1.15 or CapEx ≥ $39.0M** Threshold: EPS < $1.15^{[FMP est×0.97]}. Target: Current $71 below SMA200 $73^[FMP], if rejection continues, $62^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $1.32 vs $1.20 beat^[FMP], stock -2.6% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $39.0M^{[FMP cashflow]}. Q1 op margin 5.4%^{[FMP op margin]} — this level in Q1 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $86 (+21.4% upside vs current $71) - **High / Low:** $97 / $64 - **Buy / Hold / Sell:** 8 / 7 / 1 - **Analyst count:** 7 (last quarter), 21 all-time ## Additional Transcript Insights ### 1. market_share_gains **Claim:** Henry Schein is gaining market share in the U.S. dental market, and dental markets overall remain stable and healthy. **Evidence (transcript):** "The dental markets remain stable and healthy, and we are gaining market share." **Numbers:** — ### 2. dso_investment_equipment **Claim:** Dental practices and, in particular, DSOs are continuing to invest in equipment, and we are seeing DSOs gaining market share in the overall dental market. **Evidence (transcript):** "Dental practices and, in particular, DSOs are continuing to invest in equipment, and we are seeing DSOs gaining market share in the overall dental market." **Numbers:** — ### 3. ai_clinical_workflow **Claim:** Henry Schein's next-generation AI clinical workflow is a clear signal that our customers are ready to embrace these tools and that Henry Schein is well positioned to lead that transition. **Evidence (transcript):** "The broad level of interest in our AI solutions was a clear signal that our customers are ready to embrace these tools and that Henry Schein is well positioned to lead that transition." **Numbers:** — ### 4. operating_income_improvement **Claim:** Henry Schein is committing to the company's goal of achieving greater than $200 million of annual operating income improvement within the next few years with $125 million run rate by the end of 2026. **Evidence (transcript):** "Therefore, I am committing to the company's goal of achieving greater than $200 million of annual operating income improvement within the next few years with $125 million run rate by the end of 2026." **Numbers:** $200, $125, 2026 ### 5. ecommerce_platform_rollout **Claim:** Henry Schein has successfully rolled out its global e-commerce platform, henryschein.com to our Canadian and U.S. laboratory customers and expects to complete the U.S. rollout by the end of August. **Evidence (transcript):** "We have also successfully rolled out our global e-commerce platform, henryschein.com to our Canadian and U.S. laboratory customers. We are well advanced in implementation across the U.S. with over 80% of our U.S. dental e-commerce sales now transacted over henryschein.com. We expect to complete the U.S. rollout by the end of August" **Numbers:** 80%, August --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*